483 related articles for article (PubMed ID: 32718713)
21. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab.
Zhang X; Song K; Tong F; Fei M; Guo H; Lu Z; Wang J; Zheng C
Blood Adv; 2020 Apr; 4(7):1307-1310. PubMed ID: 32243501
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment with Remdesivir and corticosteroids in a patient with COVID-19-associated pneumonia: A case report.
Gonzales-Zamora JA; Quiroz T; Vega AD
Medwave; 2020 Aug; 20(7):e7998. PubMed ID: 32876623
[TBL] [Abstract][Full Text] [Related]
23. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C
Arch Med Res; 2020 Aug; 51(6):595-597. PubMed ID: 32482373
[TBL] [Abstract][Full Text] [Related]
24. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care.
Quartuccio L; Sonaglia A; McGonagle D; Fabris M; Peghin M; Pecori D; De Monte A; Bove T; Curcio F; Bassi F; De Vita S; Tascini C
J Clin Virol; 2020 Aug; 129():104444. PubMed ID: 32570043
[TBL] [Abstract][Full Text] [Related]
25. Proposed use of thalidomide for the cytokine storm of COVID-19.
Goihman-Yahr M
Clin Dermatol; 2020; 38(4):508. PubMed ID: 32972614
[No Abstract] [Full Text] [Related]
26. [Anti-cytokine therapy in novel coronavirus disease (COVID-19) – the first administration of tocilizumab in Hungary at a department of infectology].
Lakatos B; Gopcsa L; Gondos E; Riczu A; Várnai Z; Nagy É; Molnár E; Bekő G; Bobek I; Reményi P; Szlávik J; Sinkó J; Vályi-Nagy I
Orv Hetil; 2020 Jun; 161(26):1070-1077. PubMed ID: 32541085
[TBL] [Abstract][Full Text] [Related]
27. Outcome of COVID-19 patients with use of Tocilizumab: A single center experience.
Zain Mushtaq M; Bin Zafar Mahmood S; Jamil B; Aziz A; Ali SA
Int Immunopharmacol; 2020 Nov; 88():106926. PubMed ID: 32889236
[TBL] [Abstract][Full Text] [Related]
28. Very severe COVID-19 in the critically ill in Tunisia.
Saida IB; Ennouri E; Nachi R; Meddeb K; Mahmoud J; Thabet N; Jerbi S; Boussarsar M
Pan Afr Med J; 2020; 35(Suppl 2):136. PubMed ID: 33193951
[TBL] [Abstract][Full Text] [Related]
29. A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
Cai S; Sun W; Li M; Dong L
Clin Rheumatol; 2020 Sep; 39(9):2797-2802. PubMed ID: 32562070
[TBL] [Abstract][Full Text] [Related]
30. Tocilizumab treatment in COVID-19: A single center experience.
Luo P; Liu Y; Qiu L; Liu X; Liu D; Li J
J Med Virol; 2020 Jul; 92(7):814-818. PubMed ID: 32253759
[TBL] [Abstract][Full Text] [Related]
31. Thoughts on COVID-19 and autoimmune diseases.
Askanase AD; Khalili L; Buyon JP
Lupus Sci Med; 2020; 7(1):e000396. PubMed ID: 32341791
[TBL] [Abstract][Full Text] [Related]
32. Factors significantly associated with COVID-19 severity in symptomatic patients: A retrospective single-center study.
Hirashima T; Arai T; Kitajima H; Tamura Y; Yamada T; Hashimoto S; Morishita H; Minamoto S; Kawashima K; Kashiwa Y; Kameda M; Takeshita T; Suzuki H; Matsuoka H; Yamaguchi S; Tanaka T; Nagai T
J Infect Chemother; 2021 Jan; 27(1):76-82. PubMed ID: 33051144
[TBL] [Abstract][Full Text] [Related]
33. Treatment considerations for patients with pemphigus during the COVID-19 pandemic.
Shakshouk H; Daneshpazhooh M; Murrell DF; Lehman JS
J Am Acad Dermatol; 2020 Jun; 82(6):e235-e236. PubMed ID: 32283243
[No Abstract] [Full Text] [Related]
34. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
[TBL] [Abstract][Full Text] [Related]
35. Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience.
Birlutiu V; Birlutiu RM; Chicea L
Medicine (Baltimore); 2021 May; 100(18):e25832. PubMed ID: 33950993
[TBL] [Abstract][Full Text] [Related]
36. Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study.
Rojas-Marte G; Khalid M; Mukhtar O; Hashmi AT; Waheed MA; Ehrlich S; Aslam A; Siddiqui S; Agarwal C; Malyshev Y; Henriquez-Felipe C; Sharma D; Sharma S; Chukwuka N; Rodriguez DC; Alliu S; Le J; Shani J
QJM; 2020 Aug; 113(8):546-550. PubMed ID: 32569363
[TBL] [Abstract][Full Text] [Related]
37. Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019.
Melody M; Nelson J; Hastings J; Propst J; Smerina M; Mendez J; Guru P
Immunotherapy; 2020 Oct; 12(15):1121-1126. PubMed ID: 32546029
[No Abstract] [Full Text] [Related]
38. Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial.
León López R; Fernández SC; Limia Pérez L; Romero Palacios A; Fernández-Roldán MC; Aguilar Alonso E; Pérez Camacho I; Rodriguez-Baño J; Merchante N; Olalla J; Esteban-Moreno MÁ; Santos M; Luque-Pineda A; Torre-Cisneros J
BMJ Open; 2020 Nov; 10(11):e039951. PubMed ID: 33191263
[TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria.
Barrasa H; Rello J; Tejada S; Martín A; Balziskueta G; Vinuesa C; Fernández-Miret B; Villagra A; Vallejo A; San Sebastián A; Cabañes S; Iribarren S; Fonseca F; Maynar J;
Anaesth Crit Care Pain Med; 2020 Oct; 39(5):553-561. PubMed ID: 32278670
[TBL] [Abstract][Full Text] [Related]
40. Continuous venous hemodialysis integrated to the ECMO circuit in critically ill patient with COVID-19, a case report in Morocco.
Mounir A; Lamghari S; Raja A; Allali K; Chebbar S; Buri B; Mahdar Y; Kettani CE; Ramdani B; Ettaoumi Y; Benouna G; Barrou L
Pan Afr Med J; 2020; 35(Suppl 2):141. PubMed ID: 33193956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]